Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Express Scripts

Last Updated: May 25, 2022

CLINICAL TRIALS PROFILE FOR GLYCOPYRROLATE


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Glycopyrrolate

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Indication NCT03915561 ↗ Effect of Intravenous Dynastat on Postoperative Sore Throat Unknown status Buddhist Tzu Chi General Hospital Phase 2 2019-03-01 A postoperative sore throat (POST) after tracheal intubation is one of the most common postoperative problems causing dissatisfaction to participants, including sore throat, dry throat, cough, sputum, hoarseness and even dysphagia. Both nonpharmacological and pharmacological measures have been attempted to alleviate the incidence and severity of POST with variable success. Airway inflammation may be important in the pathogenesis of these symptoms in intubated participants but however, there was still no study to investigate the effect of cyclooxygenase-2 (COX-2) for the prevention of POST. So, the investigators' study will be the first one to investigate if perioperatively intravenous (IV) Dynastat injection can be used as a new indication for POST prevention.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Glycopyrrolate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00315536 ↗ Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children Completed University Hospital, Ghent Phase 2 2006-05-01 Study to investigate the influence of remifentanil and glycopyrrolate on cardiac index and blood pressure in children.To differentiate between contractility and the effect of the circulating volume, some of the subjects will receive additional fluid.This will be evaluated using two transthoracic echocardiac exams within the first 30 min of anesthesia.
NCT00473694 ↗ Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) Completed Merck Sharp & Dohme Corp. Phase 3 2005-11-28 The purpose of the trial is to demonstrate a faster recovery from neuromuscular block (NMB) induced with rocuronium or vecuronium after reversal by 4.0 mg/kg of Org 25969 compared with reversal by 70 μg/kg of neostigmine in combination with 14 μg/kg glycopyrrolate.
NCT00491894 ↗ Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed Shionogi Phase 3 2007-03-01 This is an open-label clinical research study of an oral glycopyrrolate liquid for the treatment of chronic moderate to severe drooling in patients with cerebral palsy or other neurological conditions. Patients participating in the study will receive oral glycopyrrolate liquid (1 mg/5 ml) three times a day (TID) for study duration of 24 weeks. After a washout, screening, and 2-day baseline period, patients will be enrolled in a 4-week dose titration period. Glycopyrrolate liquid doses will be titrated using dose levels in the Dose Titration Schedule. Titration will begin at 0.02 mg/kg per dose TID and sequentially increased in 0.02 mg/kg per dose increments TID every 5-7 days during the first four weeks until optimal individualized response is obtained for each patient or a maximum dose of 0.1 mg/kg TID is reached, not exceeding 3 mg TID or Dose-level 5 in the Dose Titration Schedule, whichever is lesser. Optimal dose for each patient is the dose at which he/she is receiving the maximum benefit from the study drug (greatest improvement in drooling) while experiencing minimum side effects. All patients will receive close attention by study staff throughout the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Glycopyrrolate

Condition Name

Condition Name for Glycopyrrolate
Intervention Trials
Chronic Obstructive Pulmonary Disease 9
Neuromuscular Blockade 9
COPD 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Glycopyrrolate
Intervention Trials
Pulmonary Disease, Chronic Obstructive 23
Lung Diseases 22
Lung Diseases, Obstructive 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Glycopyrrolate

Trials by Country

Trials by Country for Glycopyrrolate
Location Trials
United States 281
Hungary 17
Japan 17
Korea, Republic of 14
India 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Glycopyrrolate
Location Trials
New York 16
Texas 14
Oregon 13
Missouri 12
Florida 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Glycopyrrolate

Clinical Trial Phase

Clinical Trial Phase for Glycopyrrolate
Clinical Trial Phase Trials
Phase 4 53
Phase 3 19
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Glycopyrrolate
Clinical Trial Phase Trials
Completed 96
Unknown status 13
Recruiting 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Glycopyrrolate

Sponsor Name

Sponsor Name for Glycopyrrolate
Sponsor Trials
Merck Sharp & Dohme Corp. 13
Chiesi Farmaceutici S.p.A. 11
Sunovion Respiratory Development Inc. 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Glycopyrrolate
Sponsor Trials
Other 124
Industry 48
U.S. Fed 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Baxter
Harvard Business School
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.